Perspective Therapeutics says Bamzireotide delivers 37% ORR in treated NET patients

Perspective Therapeutics reported that Bamzireotide delivered a 37% objective response rate in all 68 treated NET patients, with 91% disease control and median follow-up up to 128 weeks. Grade 3 treatment-emergent adverse events occurred in 29% of patients, with no Grade 4 or 5 events.

Detected & updated continuously · Source: Nebula